How to cite item

Mighty RapaLink-1 vanquishes undruggable mutant mTOR in glioblastoma

   
@article{TCR16591,
	author = {Meena Jhanwar-Uniyal},
	title = {Mighty RapaLink-1 vanquishes undruggable mutant mTOR in glioblastoma},
	journal = {Translational Cancer Research},
	volume = {6},
	number = {Suppl 7},
	year = {2017},
	keywords = {},
	abstract = {Recent emergence of a third generation of mechanistic target of rapamycin (mTOR) inhibitors, termed RapaLink-1, have generated hope in treatment of glioblastoma, the most aggressive primary brain tumor in adults. Produced by coupling first and second generation mTOR inhibitors (1), RapaLink-1 displays superior efficacy in inhibition of the mTOR complex I (mTORC1) pathway. This led to the inhibition of proliferation with relatively longer durability in glioblastoma cells and xenograft models. Importantly, RapaLink-1 crosses the blood-brain barrier and effectively targets mutant mTOR glioblastoma cells. RapaLink-1 is a bivalent inhibitor generated by combining the analogue inhibitor of mTOR, rapamycin, with the ATP-competitive inhibitor of mTOR, MLN0128. The resulting compound is more potent than first- and second-generation mTOR inhibitors. Investigation by Fan et al. [2017] (1) examined the effect of RapaLink-1 and RapaLink-2 on glioblastoma cell growth and proliferation by targeting the mTORC1.},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/16591}
}